Amicus Operating Income from 2010 to 2026

FOLD Stock

USD 14.34 0.02 0.14%

Amicus Therapeutics' Operating Income is increasing over the years with very volatile fluctuation. Overall, Operating Income is expected to go to about 36.2 M this year. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Amicus Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

2004-12-31

Previous Quarter

34.3 M

Current Value

15.9 M

Quarterly Volatility

39.9 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check Amicus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amicus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Interest Expense of 48.5 M or Other Operating Expenses of 629.7 M, as well as many indicators such as Price To Sales Ratio of 6.58, Dividend Yield of 0.0 or PTB Ratio of 16.81. Amicus financial statements analysis is a perfect complement when working with Amicus Therapeutics Valuation or Volatility modules.

Build AI portfolio with Amicus Stock

Check out the analysis of Amicus Therapeutics Correlation against competitors.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Analyzing Amicus Therapeutics's Operating Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Income has evolved provides context for assessing Amicus Therapeutics's current valuation and future prospects.

Latest Amicus Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Amicus Therapeutics over the last few years. Operating Income is the amount of profit realized from Amicus Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Amicus Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Amicus Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amicus Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Amicus Operating Income Regression Statistics

	Arithmetic Mean	(133,976,850)
	Geometric Mean	91,309,759
	Coefficient Of Variation	(104.36)
	Mean Deviation	115,812,124
	Median	(77,211,000)
	Standard Deviation	139,823,106
	Sample Variance	19550.5T
	Range	478.2M
	R-Value	0.05
	Mean Square Error	20804.8T
	R-Squared	0
	Significance	0.85
	Slope	1,342,959
	Total Sum of Squares	312808T

Amicus Operating Income History

	2026	36.2 M
	2025	34.5 M
	2024	24.9 M
	2023	-77.2 M
	2022	-212.1 M
	2021	-206.4 M
	2020	-247 M

Other Fundumenentals of Amicus Therapeutics

Non Operating Income Net Other

Amicus Therapeutics Operating Income component correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Total Liab	Accounts Payable	Short Term Investments	Common Stock	Property Plant Equipment	Net Debt	Long Term Debt	Total Current Assets	Short Term Debt	Current Deferred Revenue	Net Tangible Assets	Net Receivables	Good Will	Capital Surpluse	Deferred Long Term Liab	Intangible Assets	Long Term Debt Total	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.83	-0.65	0.88	0.74	0.5	0.75	0.63	0.53	0.67	0.76	0.44	0.55	-0.38	0.42	0.96	0.74	0.34	0.42	0.71	-0.04	0.86	0.5	0.48	0.5
Total Stockholder Equity	0.83		-0.32	0.57	0.59	0.75	0.5	0.46	0.23	0.33	0.6	0.36	0.46	-0.04	0.08	0.79	0.44	0.36	0.4	0.35	0.02	0.69	0.46	0.51	0.16
Retained Earnings	-0.65	-0.32		-0.81	-0.53	-0.18	-0.97	-0.87	-0.9	-0.95	-0.9	-0.12	0.06	0.14	-0.92	-0.75	-0.95	0.34	0.26	-0.93	0.42	-0.81	-0.65	-0.34	-0.95
Total Liab	0.88	0.57	-0.81		0.82	0.27	0.86	0.7	0.7	0.84	0.84	0.4	0.49	-0.55	0.7	0.9	0.77	0.23	0.32	0.8	-0.39	0.79	0.55	0.3	0.71
Accounts Payable	0.74	0.59	-0.53	0.82		0.17	0.62	0.56	0.34	0.52	0.65	0.17	0.59	-0.54	0.47	0.68	0.5	0.4	0.48	0.46	-0.47	0.61	0.43	0.18	0.5
Short Term Investments	0.5	0.75	-0.18	0.27	0.17		0.33	0.33	0.35	0.3	0.5	0.08	0.0	0.38	-0.1	0.52	0.27	-0.02	0.01	0.29	0.09	0.53	0.52	0.6	-0.03
Common Stock	0.75	0.5	-0.97	0.86	0.62	0.33		0.9	0.87	0.93	0.95	0.19	0.03	-0.13	0.85	0.83	0.94	-0.23	-0.14	0.9	-0.42	0.85	0.68	0.38	0.9
Property Plant Equipment	0.63	0.46	-0.87	0.7	0.56	0.33	0.9		0.75	0.8	0.85	0.09	-0.1	0.08	0.74	0.68	0.86	-0.33	-0.25	0.77	-0.33	0.74	0.75	0.48	0.89
Net Debt	0.53	0.23	-0.9	0.7	0.34	0.35	0.87	0.75		0.95	0.86	0.04	-0.2	-0.01	0.82	0.67	0.84	-0.46	-0.39	0.92	-0.42	0.75	0.69	0.44	0.81
Long Term Debt	0.67	0.33	-0.95	0.84	0.52	0.3	0.93	0.8	0.95		0.91	0.07	-0.02	-0.16	0.85	0.77	0.9	-0.3	-0.22	0.97	-0.39	0.84	0.7	0.44	0.86
Total Current Assets	0.76	0.6	-0.9	0.84	0.65	0.5	0.95	0.85	0.86	0.91		0.11	0.05	-0.06	0.78	0.84	0.86	-0.22	-0.14	0.86	-0.5	0.87	0.83	0.56	0.79
Short Term Debt	0.44	0.36	-0.12	0.4	0.17	0.08	0.19	0.09	0.04	0.07	0.11		0.58	-0.52	0.07	0.4	0.14	0.56	0.56	0.07	0.0	0.04	0.04	0.04	0.09
Current Deferred Revenue	0.55	0.46	0.06	0.49	0.59	0.0	0.03	-0.1	-0.2	-0.02	0.05	0.58		-0.83	-0.1	0.44	-0.05	0.93	0.95	-0.04	0.01	0.17	-0.16	-0.13	-0.12
Net Tangible Assets	-0.38	-0.04	0.14	-0.55	-0.54	0.38	-0.13	0.08	-0.01	-0.16	-0.06	-0.52	-0.83		-0.22	-0.32	-0.05	-0.72	-0.75	-0.13	0.22	-0.09	0.21	0.33	-0.13
Net Receivables	0.42	0.08	-0.92	0.7	0.47	-0.1	0.85	0.74	0.82	0.85	0.78	0.07	-0.1	-0.22		0.54	0.79	-0.39	-0.32	0.79	-0.65	0.59	0.59	0.2	0.94
Good Will	0.96	0.79	-0.75	0.9	0.68	0.52	0.83	0.68	0.67	0.77	0.84	0.4	0.44	-0.32	0.54		0.8	0.19	0.27	0.78	-0.17	0.92	0.52	0.42	0.59
Capital Surpluse	0.74	0.44	-0.95	0.77	0.5	0.27	0.94	0.86	0.84	0.9	0.86	0.14	-0.05	-0.05	0.79	0.8		-0.31	-0.22	0.95	-0.2	0.87	0.63	0.47	0.88
Deferred Long Term Liab	0.34	0.36	0.34	0.23	0.4	-0.02	-0.23	-0.33	-0.46	-0.3	-0.22	0.56	0.93	-0.72	-0.39	0.19	-0.31		0.99	-0.31	0.16	-0.1	-0.34	-0.22	-0.39
Intangible Assets	0.42	0.4	0.26	0.32	0.48	0.01	-0.14	-0.25	-0.39	-0.22	-0.14	0.56	0.95	-0.75	-0.32	0.27	-0.22	0.99		-0.22	0.13	-0.01	-0.29	-0.19	-0.32
Long Term Debt Total	0.71	0.35	-0.93	0.8	0.46	0.29	0.9	0.77	0.92	0.97	0.86	0.07	-0.04	-0.13	0.79	0.78	0.95	-0.31	-0.22		-0.22	0.87	0.66	0.52	0.82
Long Term Investments	-0.04	0.02	0.42	-0.39	-0.47	0.09	-0.42	-0.33	-0.42	-0.39	-0.5	0.0	0.01	0.22	-0.65	-0.17	-0.2	0.16	0.13	-0.22		-0.11	-0.46	0.02	-0.47
Short Long Term Debt	0.86	0.69	-0.81	0.79	0.61	0.53	0.85	0.74	0.75	0.84	0.87	0.04	0.17	-0.09	0.59	0.92	0.87	-0.1	-0.01	0.87	-0.11		0.57	0.5	0.64
Net Invested Capital	0.5	0.46	-0.65	0.55	0.43	0.52	0.68	0.75	0.69	0.7	0.83	0.04	-0.16	0.21	0.59	0.52	0.63	-0.34	-0.29	0.66	-0.46	0.57		0.82	0.61
Net Working Capital	0.48	0.51	-0.34	0.3	0.18	0.6	0.38	0.48	0.44	0.44	0.56	0.04	-0.13	0.33	0.2	0.42	0.47	-0.22	-0.19	0.52	0.02	0.5	0.82		0.26
Capital Stock	0.5	0.16	-0.95	0.71	0.5	-0.03	0.9	0.89	0.81	0.86	0.79	0.09	-0.12	-0.13	0.94	0.59	0.88	-0.39	-0.32	0.82	-0.47	0.64	0.61	0.26

Click cells to compare fundamentals

About Amicus Therapeutics Financial Statements

Amicus Therapeutics stakeholders use historical fundamental indicators, such as Amicus Therapeutics' Operating Income, to determine how well the company is positioned to perform in the future. Although Amicus Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Amicus Therapeutics' assets and liabilities are reflected in the revenues and expenses on Amicus Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Amicus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	34.5 M	36.2 M
Non Operating Income Net Other	6.5 M	6.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:

How To Invest In Amicus

Details

Is Amicus Stock a good investment?

Details

What is Amicus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Amicus Therapeutics Correlation against competitors.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Will Biotechnology sector continue expanding? Could Amicus diversify its offerings? Factors like these will boost the valuation of Amicus Therapeutics. Market participants price Amicus higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Amicus Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Quarterly Earnings Growth

(0.95)

Earnings Share

(0.09)

Revenue Per Share

2.057

Quarterly Revenue Growth

0.237

Return On Assets

0.0249

The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Amicus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Amicus Operating Income from 2010 to 2026

Latest Amicus Therapeutics' Operating Income Growth Pattern

Amicus Operating Income Regression Statistics

Amicus Operating Income History

Other Fundumenentals of Amicus Therapeutics

Amicus Therapeutics Operating Income component correlations

About Amicus Therapeutics Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY